Molecular imaging in the management of cervical cancer

Journal of the Formosan Medical Association

卷:111

Koon-Kwan Ng¹  Tzu-Chen Yen²  Chyong-Huey Lai³ 

[1] Department of Medical Imaging and Intervention, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan;

[2] Department of Nuclear Medicine, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan;

[3] Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan;

关键词: cervical cancer;    molecular imaging;    MRI;    PET;    PET/CT;   

DOI  :  10.1016/j.jfma.2012.02.024

来源: DOAJ

【 摘 要 】

Positron emission tomography (PET), magnetic resonance imaging (MRI), and integrated 18-fluorodeoxyglucose (18F-FDG) PET/computed tomography are valuable techniques for assessing prognosis, treatment response after the completion of concurrent chemoradiation, suspicious or documented recurrence, unexplained post therapy elevations in tumor markers, and the response to salvage treatment when managing cervical cancer. However, PET plays a limited role in the primary staging of MRI-defined node-negative patients. Currently, 18F-FDG is still the only tracer approved for routine use, but several novel targeting PET compounds, high-Tesla MRI machines, diffusion-weighted imaging without contrast, and dynamic nuclear polarized-enhanced 13C-MR spectroscopic imaging may hold promising applications.

【 授权许可】

Unknown